The WHO estimates there were ~189 million clinical cases & 584,000 malaria-related deaths in 2013. This translates to ~1,600 child deaths daily. There is no licensed malaria vaccine & all available drugs are associated with resistant parasites. This enormous health issue is driving the search for new therapies. We address this issue by identifying new drug candidates for malaria prevention, with unique modes of action to treatment drugs in order to overcome issues of parasite drug resistance.
New Antimalarial Drug Leads Targeting Multiple Species And Life Cycle Stages
Funder
National Health and Medical Research Council
Funding Amount
$818,477.00
Summary
Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.
Combating Giardiasis By Investigating New Potent Compound Series As Leads For Improved Treatment Options
Funder
National Health and Medical Research Council
Funding Amount
$776,028.00
Summary
Giardia parasites infect ~1 billion people globally and are responsible for significant morbidity and disadvantage. There is no licensed vaccine and current treatment options are inadequate, resulting in poor compliance, treatment failures, rapid re-infection and drug resistance. New therapies are needed to combat this parasite and improve the health of millions world-wide. We will address this issue by investigating new drug candidates for the treatment of Giardia infections.
Metabolomic Analysis Of Plasmodum Falciparum And Mode Of Action Of Antimalarial Compounds
Funder
National Health and Medical Research Council
Funding Amount
$917,196.00
Summary
There is an urgent need to develop new drugs to treat malaria, one of the most important diseases to afflict humanity. We have developed new analytical approaches for measuring parasite metabolism while they live inside host cells. These approaches will be used to identify metabolic pathways that are essential for parasite infectivity and to understand the mode of action of new classes of antimalarial compounds
In 2013 there were ~200 million clinical cases of malaria, causing ~600,000 deaths. All antimalarial drugs are now associated with malaria parasite resistance. Thus, new therapies are urgently needed, including new drugs to prevent this disease. We have made the exciting discovery that an existing antimalarial drug can kill malaria parasites in a unique, previously unknown, manner. Here, we will investigate how this occurs and develop new drug candidates for malaria prevention.
Identifying Metabolic Pathways In Leishmania Parasites And Their Host Cells Required For Virulence
Funder
National Health and Medical Research Council
Funding Amount
$989,110.00
Summary
Our lack of understanding of microbial metabolism in infected animal tissues has hindered the development of effective therapies. This is particularly true for many parasitic diseases, including Leishmania spp that cause devastating disease throughout the tropics. We will utilize a range of innovative analytical and genetic approaches to identify metabolic pathway in Leishmania parasites and infected host cells that are required for virulence and are potential drug targets.
Parasitic infections are a significant global health problem, resulting in more than a million deaths annually. Unfortunately there is no licensed vaccine available for any human parasitic infection, and in many cases current drugs suffer from issues of parasite drug resistance. To address this problem this project brings together leading researchers from the European Union, Brazil, and Australia to discover and develop new types of drugs for four major human parasitic diseases: schistosomiasis, ....Parasitic infections are a significant global health problem, resulting in more than a million deaths annually. Unfortunately there is no licensed vaccine available for any human parasitic infection, and in many cases current drugs suffer from issues of parasite drug resistance. To address this problem this project brings together leading researchers from the European Union, Brazil, and Australia to discover and develop new types of drugs for four major human parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.Read moreRead less
Insights Into The Biology Of The Carcinogenic Blood Fluke, Schistosoma Haematobium – A First Response To The Wake-up Call
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
Schistosoma haematobium is a seriously neglected parasite that infects > 100 million people. Chronic infection severely affects the urino-genital system and causes malignant bladder cancer. Advanced technologies will be used to explore, for the first time, the molecular biology of this parasite, design new strategies to fight this insidious pathogen and understand how it induces cancer.
Investigating The Therapeutic Potential Of FTY720 For Human African Trypanosomiasis
Funder
National Health and Medical Research Council
Funding Amount
$653,736.00
Summary
FTY720, is a drug currently used to treat multiple sclerosis, which we have shown is also be able to kill the parasite responsible for African sleeping sickness, Trypanosomes. We aim to identify the target the drug acts on in the parasite to have its affect. Our objective is to improve the activity further by chemical modification to produce a potent, orally available and well characterised, non-toxic drug suitable for preclinical development.
Scabies Mite Intestinal Proteases As Targets For Novel Therapeutics.
Funder
National Health and Medical Research Council
Funding Amount
$672,533.00
Summary
Scabies causes bacterial disease affecting poor people worldwide. Available therapies are limited and drug resistance is emerging. We investigate molecules that the mite needs to infest the skin, to guide the formulation and the testing of novel drugs. This will provide improved treatment of affected individuals and their families, thereby reducing the spread of scabies and bacterial infections and their devastating sequelae, particularly in Australian Indigenous communities.